Luzalba Sanoja-Flores
Overview
Explore the profile of Luzalba Sanoja-Flores including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
325
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sierro-Martinez B, Escamilla-Gomez V, Perez-Ortega L, Guijarro-Albaladejo B, Hernandez-Diaz P, de la Rosa-Garrido M, et al.
Cell Oncol (Dordr)
. 2024 Aug;
48(1):219-237.
PMID: 39192092
Purpose: CAR therapy targeting BCMA is under investigation as treatment for multiple myeloma. However, given the lack of plateau in most studies, pursuing more effective alternatives is imperative. We present...
2.
Perez-Escurza O, Flores-Montero J, Oskarsson J, Sanoja-Flores L, Del Pozo J, Lecrevisse Q, et al.
Blood Cancer J
. 2023 Dec;
13(1):182.
PMID: 38072838
Monoclonal gammopathy of undetermined significance (MGUS) is the earliest discernible stage of multiple myeloma (MM) and Waldenström's macroglobulinemia (WM). Early diagnosis of MG may be compromised by the low-level infiltration,...
3.
Garcia-Calderon C, Sierro-Martinez B, Garcia-Guerrero E, Sanoja-Flores L, Munoz-Garcia R, Ruiz-Maldonado V, et al.
Front Immunol
. 2023 May;
14:1152498.
PMID: 37122702
Purpose: CAR-T cell therapy has proven to be a disruptive treatment in the hematology field, however, less than 50% of patients maintain long-term response and early predictors of outcome are...
4.
Dos Santos Salgado A, Magalhaes R, Pontes R, Barbosa E, Flores-Montero J, Sanoja-Flores L, et al.
Cancers (Basel)
. 2023 Mar;
15(5).
PMID: 36900396
Despite recent advances in multiple myeloma (MM), the incorporation of novel agents and measurable residual disease (MRD) monitoring in low-income countries remains a challenge. Although lenalidomide maintenance (M-Len) after autologous...
5.
Garces J, Cedena M, Puig N, Burgos L, Perez J, Cordon L, et al.
J Clin Oncol
. 2022 Jun;
40(27):3151-3161.
PMID: 35666958
Purpose: Patients with multiple myeloma (MM) may show patchy bone marrow (BM) infiltration and extramedullary disease. Notwithstanding, quantification of plasma cells (PCs) continues to be performed in BM since the...
6.
Puig N, Flores-Montero J, Burgos L, Cedena M, Cordon L, Perez J, et al.
Cancers (Basel)
. 2021 Oct;
13(19).
PMID: 34638406
Background: Whereas, in most patients with multiple myeloma (MM), achieving undetectable MRD anticipates a favorable outcome, some others relapse shortly afterwards. Although one obvious explanation for this inconsistency is the...
7.
de Pontes R, Flores-Montero J, Sanoja-Flores L, Puig N, Pessoa de Magalhaes R, Corral-Mateos A, et al.
Cancers (Basel)
. 2021 Apr;
13(7).
PMID: 33916787
B-cell regeneration during therapy has been considered as a strong prognostic factor in multiple myeloma (MM). However, the effects of therapy and hemodilution in bone marrow (BM) B-cell recovery have...
8.
Damasceno D, Almeida J, Teodosio C, Sanoja-Flores L, Mayado A, Perez-Pons A, et al.
Cancers (Basel)
. 2021 Apr;
13(6).
PMID: 33810169
Background: Monocyte/macrophages have been shown to be altered in monoclonal gammopathy of undetermined significance (MGUS), smoldering (SMM) and active multiple myeloma (MM), with an impact on the disruption of the...
9.
Sanoja-Flores L, Flores-Montero J, Perez-Andres M, Puig N, Orfao A
Cancers (Basel)
. 2020 Jun;
12(6).
PMID: 32521788
Cancer dissemination and distant metastasis most frequently require the release of tumor cells into the blood circulation, both in solid tumors and most hematological malignancies, including plasma cell neoplasms. However,...
10.
Garces J, Bretones G, Burgos L, Valdes-Mas R, Puig N, Cedena M, et al.
Leukemia
. 2020 Jun;
34(11):3007-3018.
PMID: 32475991
Multiple myeloma (MM) patients undergo repetitive bone marrow (BM) aspirates for genetic characterization. Circulating tumor cells (CTCs) are detectable in peripheral blood (PB) of virtually all MM cases and are...